The CASP8 rs3834129 polymorphism and breast cancer risk in BRCA1 mutation carriers

Breast Cancer Res Treat. 2011 Feb;125(3):855-60. doi: 10.1007/s10549-010-1068-8. Epub 2010 Jul 22.

Abstract

The rs3834129 polymorphism, in the promoter of CASP8 gene, has been recently reported as associated with breast cancer risk in the general population, with the minor allele del having a protective effect. Some of the genetic variants found associated with breast cancer risk were reported as risk modifiers in individuals with mutations in BRCA1 and BRCA2 genes. Here, we tested the effect of the rs3834129 del allele on breast cancer risk in BRCA mutation carriers. The rs3834129 was genotyped in a total of 1,207 Italian female BRCA mutation carriers. Of these, 740 carried a BRCA1 mutation and 467 a BRCA2 mutation. Overall, 699 were affected with breast cancer and 508 were unaffected. When considering class 1 (loss-of-function) BRCA mutations, hazard ratios estimated by weighted multivariable Cox regression model, for individuals with at least one copy of the del allele, were 1.46 (95% confidence interval (CI): 1.08-1.99) for BRCA1 and BRCA2 mutation carriers combined, 1.74 (95% CI: 1.24-2.46) for BRCA1 mutation carriers, and 1.09 (95% CI: 0.66-1.80) for BRCA2 mutation carriers. These results suggest that the minor allele del of rs3834129 is associated under a dominant model with increased breast cancer risk in carriers of BRCA1 mutations but not in carriers of BRCA2 mutations.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Breast Neoplasms / genetics*
  • Caspase 8 / genetics*
  • DNA Mutational Analysis
  • Female
  • Genes, BRCA1*
  • Genes, BRCA2
  • Genotype
  • Heterozygote
  • Humans
  • Italy
  • Mutation*
  • Polymorphism, Genetic*
  • Proportional Hazards Models
  • Risk

Substances

  • Caspase 8